KNTPF - Week In Review: Biopharma Deals Slow During China New Year Week

• Shanghai's HanBio Therapeutics raised $40 million in a Series A financing to advance its innovative biologic products. HanBio’s pipeline includes three bispecific antibodies in the IND and pre-IND stages, and a variety of early-stage antibodies and other biologics products.
• Sweden's Xvivo Perfusion AB announced its ready-to-use lung perfusion product, Perfadex Plus, was approved for China use with lung transplants.
• Shanghai Hutchmed started a China Phase Ib/II study of its novel FGFR 1/2/3 inhibitor combined with chemotherapy or toripalimab, an anti-PD-1 therapy.

For further details see: